EGFR and non-small cell lung carcinoma: The risk score was a prognostic biomarker for predicting both OS and PFS in NSCLC patients with EGFR exon19Del mutation, EGFR L858R mutation, TNM stage IV, LUAD, and treatment with gefitinib, and predicting PFS in patients with young (< 60 y), male, and not receiving surgery treatment (Figures S8–S10).